The Integris Medtech IPO is an upcoming mainboard Bookbuilding offer (Fresh capital cum OFS) scheduled to open on 27 November 2026. The Integris Medtech IPO will close on 1 December 2026. The Integris Medtech IPO has a face value of ₹1 and a lot size of 0 shares. The Integris Medtech IPO size aggregates up to ₹600 crore, listing on NSE & BSE on 4 December 2026. The Integris Medtech IPO allotment is expected on 2 December 2026.
On the financial front, the Integris Medtech IPO reported revenue of ₹509 crore for 30 Jun 2025, compared with ₹1,960 crore for 31 Mar 2025. The Integris Medtech IPO PAT was ₹268 crore against ₹71 crore. The Integris Medtech IPO EBITDA stood at ₹79 crore with a 16.26% margin. The Integris Medtech IPO net worth as of 30 Jun 2025 was ₹3,890 crore.
Always verify The Integris Medtech IPO details and GMP data with the official offer document before investing in the Integris Medtech IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Jun 2025
31 Mar 2025
31 Mar 2024
Total Assets
4,020
3,641
2,989
Revenue
509
1,960
1,582
PAT
268
71
-5
EBITDA
79
309
190
Net Worth
3,890
2,753
2,681
Reserves
2,300
1,151
1,136
Total Borrowing
793
1,729
813
Integris Medtech IPO Financials FAQs
Revenue of Integris Medtech (Amount in ₹ Crore) — 30 Jun 2025: 509; 31 Mar 2025: 1,960; 31 Mar 2024: 1,582. Profit after tax (PAT) — 30 Jun 2025: 268; 31 Mar 2025: 71; 31 Mar 2024: -5.
EBITDA of Integris Medtech (Amount in ₹ Crore) — 30 Jun 2025: 79; 31 Mar 2025: 309; 31 Mar 2024: 190. The EBITDA margin is 16.26%.
Total assets — 30 Jun 2025: 4,020; 31 Mar 2025: 3,641; 31 Mar 2024: 2,989. Net worth — 30 Jun 2025: 3,890; 31 Mar 2025: 2,753; 31 Mar 2024: 2,681. Reserves & surplus — 30 Jun 2025: 2,300; 31 Mar 2025: 1,151; 31 Mar 2024: 1,136. (Amount in ₹ Crore)
Total borrowing of Integris Medtech (Amount in ₹ Crore) — 30 Jun 2025: 793; 31 Mar 2025: 1,729; 31 Mar 2024: 813.
The financials shown for Integris Medtech IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.